| Date | Title | | | 08/03/16 | Entellus Medical Announces Second Quarter 2016 Financial Results| PLYMOUTH, Minn., Aug. 03, 2016 (GLOBE NEWSWIRE) -- Entellus Medical, Inc. (the “Company” or “Entellus Medical”) (NASDAQ:ENTL), a medical technology company focused on delivering superior patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis patients, today reported its financial results for the quarter ended June 30, 2016.
Recent Highlights and Accomplishments
Revenue of $18.7 million in the second quarter o... |
| | | 07/27/16 | Entellus Medical to Present at the Canaccord Genuity Growth Conference| PLYMOUTH, Minn., July 27, 2016 (GLOBE NEWSWIRE) -- Entellus Medical, Inc. (NASDAQ:ENTL), a medical technology company focused on delivering superior patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis patients, today announced the company plans to participate in the 36th Annual Growth Conference hosted by Canaccord Genuity in Boston, MA.
Entellus Medical’s management is scheduled to present on Wednesday, August ... |
| | | 07/12/16 | Entellus Medical to Report Second Quarter 2016 Financial Results on August 3, 2016| Conference call scheduled for Wednesday, August 3, 2016 at 3:30pm CT / 4:30pm ET
PLYMOUTH, Minn., July 12, 2016 (GLOBE NEWSWIRE) -- Entellus Medical, Inc. (NASDAQ:ENTL), a medical technology company focused on delivering superior patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis patients, today announced that it will release its financial results for the second quarter 2016 after the close of trading on Wednesda... |
| | | 06/29/16 | Entellus Medical Acquires XeroGel™ from CogENT Therapeutics®, Strengthens Product Portfolio| Reiterates 2016 Financial Outlook
PLYMOUTH, Minn., June 29, 2016 (GLOBE NEWSWIRE) -- Entellus Medical, Inc. (NASDAQ:ENTL) today announced it has acquired and entered into an exclusive license for the XeroGel assets with CogENT Therapeutics, LLC for $11 million in cash. Under terms of the agreements, Entellus has become the manufacturer of XeroGel and will continue to market and sell XeroGel to hospitals, offices, clinics and ambulatory surgery centers. This transaction delivers on Entellus’s... |
| | | 06/27/16 | Entellus Medical and Fiagon Announce Expanded Agreement to Include Hospital-Based Customers| Introduction of the Premium Fiagon Navigation System for hospital customers, complete with more advanced ENT and cranio-maxillofacial (CMF) applications
PLYMOUTH, Minn. and AUSTIN, Texas, June 27, 2016 (GLOBE NEWSWIRE) -- Entellus Medical, Inc. (NASDAQ:ENTL) and Fiagon NA Corporation announced today that they have expanded their agreement allowing Entellus to exclusively distribute Fiagon branded Navigation Systems and accessories in the United States and Canada. The expanded agreement enabl... |
| | | 06/02/16 | Entellus Medical to Present at the William Blair Growth Stock Conference| PLYMOUTH, Minn., June 02, 2016 (GLOBE NEWSWIRE) -- Entellus Medical, Inc. (NASDAQ:ENTL), a medical technology company focused on delivering superior patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis patients, today announced the company plans to participate in the 36th Annual Growth Stock Conference hosted by William Blair in Chicago, IL.
Entellus Medical’s management is scheduled to present on Wednesday, June... |
| | | 05/23/16 | Entellus Medical Names Brent Moen Chief Financial Officer| PLYMOUTH, Minn., May 23, 2016 (GLOBE NEWSWIRE) -- Entellus Medical, Inc. (NASDAQ:ENTL), a medical technology company focused on delivering superior patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis patients, today announced the appointment of Brent Moen as Chief Financial Officer and Corporate Secretary, effective immediately. Thomas Griffin, the Company’s current CFO, is assuming the newly created position of V... |
| | | 05/19/16 | Entellus Medical Announces Presentation of Positive Clinical Study Results for XprESS in Pediatric Patients| Balloon Sinus Dilation Determined to be Safe and Effective for Children with CRS Aged Two Years and Older
PLYMOUTH, Minn. and CHICAGO, May 19, 2016 (GLOBE NEWSWIRE) -- Entellus Medical, Inc. (NASDAQ:ENTL) announced today that Dr. Zachary M. Soler, MD, MSc, Medical University of South Carolina, presented the results of a prospective, multicenter study of children with chronic rhinosinusitis (CRS) treated with the XprESS™ Multi-Sinus Dilation System. The results were presented at the Combined O... |
| | | 05/04/16 | Entellus Medical Announces First Quarter 2016 Financial Results| PLYMOUTH, Minn., May 04, 2016 (GLOBE NEWSWIRE) -- Entellus Medical, Inc. (NASDAQ:ENTL), a medical technology company focused on delivering superior patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis patients, today reported its financial results for the quarter ended March 31, 2016.
Recent Highlights and Accomplishments
Revenue of $16.9 million in the first quarter of 2016, an increase of 25% year-over-y... |
| | | 04/18/16 | Entellus Medical to Report First Quarter 2016 Financial Results on May 4, 2016| Conference call scheduled for Wednesday, May 4, 2016 at 3:30pm CT / 4:30pm ET
PLYMOUTH, Minn., April 18, 2016 (GLOBE NEWSWIRE) -- Entellus Medical, Inc. (NASDAQ:ENTL), a medical technology company focused on delivering superior patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis patients, today announced that it will release its financial results for the first quarter 2016 after the close of trading on Wednesday, ... |
| | | 02/24/16 | Entellus Medical Announces Fourth Quarter and Full Year 2015 Financial Results and Issues 2016 Financial Outlook| PLYMOUTH, Minn., Feb. 24, 2016 (GLOBE NEWSWIRE) -- Entellus Medical, Inc. (NASDAQ:ENTL), a medical technology company focused on delivering superior patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis patients, today reported its financial results for the quarter and year ended December 31, 2015.
Recent Highlights and Accomplishments
Achieved net revenue of $61.6 million in 2015, an increase of 26% year-o... |
| | | 02/10/16 | Entellus Medical to Report Fourth Quarter and Year-End 2015 Financial Results on February 24, 2016| Conference Call Scheduled for Wednesday, February 24, 2016 at 4:30pm ET
PLYMOUTH, Minn., Feb. 10, 2016 (GLOBE NEWSWIRE) -- Entellus Medical, Inc. (NASDAQ:ENTL), a medical technology company focused on delivering superior patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis patients, today announced that it will release its financial results for the fourth quarter and year-end 2015 after the close of trading on Wedn... |
| | | 01/28/16 | Entellus Medical to Present at the Leerink Partners 5th Annual Global Healthcare Conference| PLYMOUTH, Minn., Jan. 28, 2016 (GLOBE NEWSWIRE) -- Entellus Medical, Inc. (NASDAQ:ENTL), a medical technology company focused on delivering superior patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis patients, today announced the company plans to participate in the Leerink Partners 5th Annual Global Healthcare Conference in New York, NY.
Entellus Medical’s management is scheduled to present on Thursday, Februar... |
| |
|
Print Page | 
E-mail Page | 
RSS Feeds | 
E-mail Alerts | 
Financial Tear Sheet